Evaluation of Topical Sertaconazole Efficacy with Cryotherapy versus Cryotherapy with placebo in Treatment of Cutaneous Leishmaniasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180623040195N1

Enrollment

Registered

2018-08-01

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneus Leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: Intervention group: For these patients, once a week, cryotherapy was performed, for the maximum duration of 8 weeks and used Sertaconazole QD for 8 weeks. Intervention 2: Control group

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients above 12 years old Numbers of lesions are less than 3 Diameter of the lesions are less than 3 cm Positive smear for leishmaniasis Less than 4 months from the onset of the lesion

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Unwillingness to participate in the study Known cases of systemic diseases

Design outcomes

Primary

Measure	Time frame
Area of the lesion. Timepoint: The 0, 2, 4 and 8 weeks. Method of measurement: Using the rule and measurement of the diameters of lesion.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farideh Jowkar

Shiraz University of Medical Sciences

jowkarf@yahoo.com+98 71 3212 5592

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026